AU2002224240A1 - Colostrum-based composition - Google Patents

Colostrum-based composition

Info

Publication number
AU2002224240A1
AU2002224240A1 AU2002224240A AU2424002A AU2002224240A1 AU 2002224240 A1 AU2002224240 A1 AU 2002224240A1 AU 2002224240 A AU2002224240 A AU 2002224240A AU 2424002 A AU2424002 A AU 2424002A AU 2002224240 A1 AU2002224240 A1 AU 2002224240A1
Authority
AU
Australia
Prior art keywords
colostrum
composition
milk
derived product
hyperimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002224240A
Other languages
English (en)
Inventor
Peter Graeme Hobman
Charles Edward Williams
Simon Stephen Yarrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fonterra Cooperative Group Ltd
Original Assignee
Fonterra Cooperative Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fonterra Cooperative Group Ltd filed Critical Fonterra Cooperative Group Ltd
Publication of AU2002224240A1 publication Critical patent/AU2002224240A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002224240A 2000-11-15 2001-11-15 Colostrum-based composition Abandoned AU2002224240A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ50823400 2000-11-15
NZ508234 2000-11-15
PCT/NZ2001/000256 WO2002040051A1 (en) 2000-11-15 2001-11-15 Colostrum-based composition

Publications (1)

Publication Number Publication Date
AU2002224240A1 true AU2002224240A1 (en) 2002-05-27

Family

ID=19928242

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002224240A Abandoned AU2002224240A1 (en) 2000-11-15 2001-11-15 Colostrum-based composition

Country Status (8)

Country Link
US (2) US20040047856A1 (zh)
EP (1) EP1341554A4 (zh)
JP (1) JP2004517067A (zh)
KR (1) KR20030051822A (zh)
CN (1) CN1299771C (zh)
AU (1) AU2002224240A1 (zh)
HU (1) HUP0400589A3 (zh)
WO (1) WO2002040051A1 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100268658A1 (en) * 2001-05-14 2010-10-21 Prolacta Bioscience Method for collecting, testing and distributing milk
US20020182243A1 (en) * 2001-05-14 2002-12-05 Medo Elena Maria Method of producing nutritional products from human milk tissue and compositions thereof
WO2003080082A1 (en) * 2002-03-21 2003-10-02 Anadis Ltd Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment
SE0203265D0 (sv) * 2002-11-06 2002-11-06 Coloplus Ab A feed or food product composition
US20040137072A1 (en) * 2003-01-13 2004-07-15 Richard Cockrum Method for increasing calcium absorption and bone mineral density through the supplementation of bovine colostrum
US6998392B2 (en) 2003-04-02 2006-02-14 Mti Meta Tech Inc. Formulation to treat or prevent parasitic infection
US7851451B2 (en) * 2004-03-12 2010-12-14 Mti Meta Tech Inc. Formulations for mediating inflammatory bowel disorders
US8536140B2 (en) * 2004-03-12 2013-09-17 Mti Meta Tech Inc. Methods for treating inflammatory bowel disease
JP4965063B2 (ja) * 2004-05-07 2012-07-04 雪印メグミルク株式会社 口腔内細菌叢改善剤、抗菌剤及び生育促進剤。
US20060013890A1 (en) * 2004-06-24 2006-01-19 Green Shawn J Dairy-derived anticholesterol immunoglobulin to lower dietary cholesterol in humans
US20070025980A1 (en) * 2005-07-27 2007-02-01 Krogsgaard David L Composition permitting muscle growth while protecting joint health
WO2007035870A2 (en) 2005-09-20 2007-03-29 Prolacta Bioscience, Inc. A method for testing milk
JP5035865B2 (ja) * 2005-09-26 2012-09-26 国立大学法人高知大学 Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ菌株の増殖・運動抑制方法
US20070087002A1 (en) * 2005-10-14 2007-04-19 Green Shawn J Anticholesterol immunoglobulin to treat lipid raft diseases
US8071101B2 (en) 2005-11-03 2011-12-06 Avaxia Biologics, Inc. Antibody therapy for treatment of diseases associated with gluten intolerance
DK2392343T3 (en) * 2006-07-03 2019-01-28 Perraudin Jean Paul Antimicrobial compositions comprising hypohalite and / or hypothiocyanite and applications thereof
CA2706722C (en) * 2006-11-29 2016-01-12 Prolacta Bioscience, Inc. Human milk compositions and methods of making and using same
JP5616066B2 (ja) * 2006-12-08 2014-10-29 プロラクタ バイオサイエンス，インコーポレイテッド ヒト脂質組成物ならびにその製造および使用方法
EP2215474A4 (en) * 2007-07-16 2012-07-18 Avaxia Biologics Inc ANTIBODY THERAPY FOR MODULATING THE FUNCTION OF DARM RECEPTORS
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US8927027B2 (en) 2008-12-02 2015-01-06 Prolacta Bioscience Human milk permeate compositions and methods of making and using same
US20110020461A1 (en) * 2009-07-27 2011-01-27 Harry Leneau Hyaluronate and colostrum compositions and methods of using the same
US20110086017A1 (en) * 2009-10-08 2011-04-14 Svetlana Kravets Medical Food composition and methods for management of inflammatory processes in mammals
NL2004099C2 (en) * 2010-01-15 2011-07-18 Friesland Brands Bv Milk derived antigen specific antibodies for inducing an adaptive immune response, methods of preparation and uses thereof.
CN103987265B (zh) 2011-08-03 2017-05-24 普罗莱克塔生物科学公司 减少细菌污染的人乳微滤
WO2014100191A1 (en) * 2012-12-18 2014-06-26 Abbott Laboratories Nutritional compositions comprising neuroprotective dietary oligosaccharides
ES2843254T3 (es) 2013-03-13 2021-07-16 Prolacta Bioscience Inc Productos de leche humana rica en grasas
EP3397064A4 (en) 2015-12-30 2019-10-30 Prolacta Bioscience, Inc. HUMAN MILK PRODUCTS USEFUL IN PRE- AND POST-OPERATIVE CARE
CN107684078A (zh) * 2017-10-19 2018-02-13 深圳市德荟堂生物科技有限公司 一种乳钙制品及其生产工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879110A (en) * 1983-10-27 1989-11-07 Stolle Research And Development Corporation Antihypertensive hyperimmune milk, production, composition, and use
JPH0768135B2 (ja) * 1985-03-29 1995-07-26 株式会社ヤクルト本社 ボツリヌス毒素の中和剤
US5198213A (en) * 1985-04-15 1993-03-30 Protein Technology, Inc. Method of disease treatment utilizing an immunologically whey fraction
US4699789A (en) * 1985-09-27 1987-10-13 Eastern Artificial Insemination Cooperative, Inc. Viral free semen and methods of producing the same
US6015882A (en) * 1992-05-29 2000-01-18 The Regents Of The University Of California Vaccines, antibodies, proteins, glycoproteins, DNAs and RNAs for prophylaxis and treatment of Cryptosporidium parvum infections
CA2089630A1 (en) * 1992-11-05 1994-05-06 Cesar M. Libenson Process for obtaining antibodies against human and animal immunoglobulins from the colostrum and milk for mammals immunized with the respective immunoglobulins
US5591434A (en) * 1993-05-26 1997-01-07 The United States Of America As Represented By The Secretary Of Agriculture DNA sequence encoding surface protein of cryptosporidium parvum
WO1998007320A1 (en) * 1996-08-23 1998-02-26 North Carolina State University NEUTRALIZATION-SENSITIVE EPITOPES OF $i(CRYPTOSPORIDIUM PARVUM)
DK1248646T3 (da) * 1999-12-21 2008-05-19 Merial Sas Præparater og vacciner indeholdende antigen(er) fra cryptosporidium parvum og fra andet enterisk patogen

Also Published As

Publication number Publication date
US20050220894A1 (en) 2005-10-06
CN1486194A (zh) 2004-03-31
CN1299771C (zh) 2007-02-14
HUP0400589A3 (en) 2005-06-28
US20040047856A1 (en) 2004-03-11
WO2002040051A1 (en) 2002-05-23
EP1341554A1 (en) 2003-09-10
EP1341554A4 (en) 2005-06-15
JP2004517067A (ja) 2004-06-10
HUP0400589A2 (hu) 2004-06-28
KR20030051822A (ko) 2003-06-25

Similar Documents

Publication Publication Date Title
AU2002224240A1 (en) Colostrum-based composition
Sripanyakorn et al. Dietary silicon and bone health
Newburg Bioactive components of human milk: evolution, efficiency, and protection
US4762822A (en) Reduction of gastrointestinal disease-producing organisms with sialic acid and gangliosides
US8703699B2 (en) Lactoferrin
Kang et al. Modulation of lipid metabolism by mixtures of protamine and chitooligosaccharide through pancreatic lipase inhibitory activity in a rat model
CZ2003535A3 (cs) Potravinářský prostředek
CA2442053A1 (en) Composition comprising a prebiotic for decreasing inflammatory process and abnormal activation of non-specific immune parameters
IE950335A1 (en) Use of proteins from bovine colostrum to treat failure of¹passive transfer, to promote growth and to improve milk¹production in bovine species
PL190301B1 (pl) Zastosowanie lektyn i środek farmaceutyczny
EP1010424B1 (en) Liver fat accumulation inhibitory composition, food additive for liver fat accumulation inhibition, and method of inhibiting liver fat accumulation
DE69901051D1 (de) Zusammensetzungen, die einen Guggul-Extrakt mit Phosphatsalzen enthalten
JP2000232864A (ja) 麦若葉末を含有する食品
FI107432B (fi) Mikrokiteisen kitosaanin käyttö
DE69032646T2 (de) Eine caseinfraktion zur therapeutischen vorbeugenden und/oder diagnostischen verwendung bei atemweginfektionen
CA2405553C (en) Bone-strengthening agent, bone-strengthening food and bone-strengthening feed composition
WO2001005356A3 (en) Weight control product comprising a synergistic mixture of guggul extract, phosphate salt and metabolic stimulant
Rosalen et al. Effect of copper co-crystallized with sugar on caries development in desalivated rats
US20170295836A1 (en) Nutritional powders comprising spray dried hmb
JP3110020B2 (ja) ヘリコバクターピロリの除菌剤
JP6560471B1 (ja) 骨形成促進剤、並びにこれを用いた骨代謝疾患の予防および／または治療剤
JP3521067B2 (ja) 大腸菌感染防止剤
JP7134703B2 (ja) 副腎機能低下抑制剤
JP2001131065A (ja) 体脂肪減少促進剤及び体脂肪減少促進用食品組成物
AU8723501A (en) Compositions and methods for human gastrointestinal health

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted